measurement of lipoprotein(a): Plasma lipoprotein(a) will be measured in the biological relatives group as part of a clinical health care development project
Study summary
The aim of the current project is to evaluate the penetrance of elevated plasma Lp(a) levels in patients with atherosclerotic coronary artery disease to their first- and second-degree biological relatives based on data from a clinical health care development project.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria
* participation in the clinical health care development project
* established atherosclerotic coronary artery disease
Exclusion Criteria:
* diagnosis of familial hypercholesterolemia
* chronic kidney disease stadium ≥4
Primary outcome measure(s)
Difference in proportion of elevated plasma lipoprotein(a) between index and first degree relatives — Dataset will be analysed after completion of health care development project (anticipated March 2025) Difference in proportion of low, intermediate and high plasma lipoprotein(a) levels between first degree relatives stratified on index patients Lp(a) level (i.e low, intermediate, high)
Difference in proportion of elevated plasma lipoprotein(a) between index and second degree relatives — Dataset will be analysed after completion of health care development project (anticipated March 2025) Difference in proportion of low, intermediate and high plasma lipoprotein(a) levels between second degree relatives stratified on index patients Lp(a) level (i.e low, intermediate, high)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
